Pharma stock with revenue growth guidance of 350% to add to your watchlist

This Pharma stock, is engaged in manufacturing high‑purity pharmaceutical intermediates and active pharmaceutical ingredients used by pharma, nutraceutical, personal care, and animal health companies in India and export markets, is in focus after the management gave guidance of 350 percent revenue growth for FY28.

With a market capitalization of Rs. 881.78 crore, the shares of Anlon Healthcare Limited were currently trading at Rs. 165.90 per equity share, down nearly 1.75 percent from its previous day’s close price of Rs. 168.85. 

Management Guidance

Anlon Healthcare Limited has presented a strong growth outlook for the next few years. The company expects its revenue to rise to Rs. 360-400 crore in FY27, which represents a 233.33 percent increase compared to FY25 revenue of Rs. 120 crore.  By FY28, with three facilities operational, Anlon is targeting Rs. 520-540 crore, reflecting a 350 percent increase over FY25. 

Margin Guidance

Anlon Healthcare Limited expects a blended EBITDA margin of 25-27 percent on an annual basis, and management has firmly stated that the EBITDA margin will not fall below 25 percent.

Order book Guidance

The company has a confirmed order book of Rs. 380 crore for next year, providing strong revenue visibility. Nearly 50 percent of these orders come from exports, highlighting growing international demand and a strengthening global presence.

Additionally, Management has also reiterated its ambition to deliver more than 30 percent revenue CAGR over the next three years, showing confidence in its expansion strategy and market potential.

Capex

The company has outlined a focused capex plan, including at least Rs. 32 crore for its greenfield expansion project. In addition, it is evaluating an inorganic acquisition worth Rs. 50-55 crore, which will be entirely separate from the greenfield investment.

Export Business Growth

The company expects strong growth in its export business, with exports projected to reach around 30 percent in FY26. By FY27, management is confident that exports will contribute at least 60 percent of total revenue, reflecting a sharp increase in global demand.

Company Overview

Anlon Healthcare Limited was incorporated in 2013 and is based in Rajkot, Gujarat. The company has grown as a research-focused chemical manufacturer serving the pharmaceutical industry in India and export markets

The company is engaged in manufacturing high-purity pharmaceutical intermediates and active pharmaceutical ingredients used as raw materials for medicines, nutraceuticals, personal care, and animal health products. It focuses on quality and regulatory compliance with major international health standards.

Anlon Healthcare Limited produces a wide range of intermediates and APIs, including pain and inflammation drugs and other specialty molecules, supported by in-house R&D labs and quality-control facilities. It offers custom manufacturing services for complex and niche chemical products.

Recent quarter results

Coming into financial highlights, Anlon Healthcare Limited’s revenue has increased from Rs. 24.17 crore in Q2 FY25 to Rs. 52.20 crore in Q2 FY26, which has grown by 115.97 percent. The net profit has also grown by 259.85 percent from Rs. 2.59 crore in Q2 FY25 to Rs. 9.32 crore in Q2 FY26. Anlon Healthcare Limited’s revenue and net profit have grown at a CAGR of 3.05 percent and 87.08 percent, respectively, over the last two years.

In terms of return ratios, the company’s ROCE and ROE stand at 24.8 percent and 40.4 percent, respectively. Anlon Healthcare Limited has an earnings per share (EPS) of Rs. 5.15, and its debt-to-equity ratio is 0.27x.

Written By – Nikhil Naik

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock with revenue growth guidance of 350% to add to your watchlist appeared first on Trade Brains.